Soleus Capital Amends VYNE Therapeutics Stake as of Dec 31, 2023

TL;DR

**Soleus Capital updated its VYNE Therapeutics holdings, signaling a potential shift in institutional interest.**

AI Summary

Soleus Capital Master Fund, L.P. filed an amendment to their Schedule 13G, indicating a change in their ownership of VYNE Therapeutics Inc. common stock as of December 31, 2023. This filing, an Amendment No. 1, updates their previous disclosure regarding their stake in VYNE Therapeutics, a pharmaceutical preparations company. This matters to investors because significant changes in institutional ownership can signal shifts in confidence or strategy regarding the stock.

Why It Matters

Changes in major institutional holdings can influence stock price and investor sentiment, as they often reflect a fund's updated view on a company's prospects.

Risk Assessment

Risk Level: low — This filing is an update to an existing ownership disclosure and does not inherently indicate a high-risk event, but rather a routine reporting change.

Analyst Insight

Investors should monitor subsequent filings from Soleus Capital Master Fund, L.P. to understand the full scope of their updated position in VYNE Therapeutics Inc. and assess if other institutional investors are making similar moves.

Key Players & Entities

• Soleus Capital Master Fund, L.P. (company) — the reporting person filing the SC 13G/A amendment
• VYNE Therapeutics Inc. (company) — the subject company whose common stock is being reported
• December 31, 2023 (date) — the date of the event requiring the filing of this statement
• 0001566044 (number) — Central Index Key (CIK) for VYNE Therapeutics Inc.
• 92941V 308 (number) — CUSIP Number for VYNE Therapeutics Inc. Common Stock

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• ea192420-13ga1soleus_vyne.htm (SC 13G/A) — 138KB
• 0001213900-24-009367.txt ( ) — 140KB

From the Filing

SC 13G/A 1 ea192420-13ga1soleus_vyne.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* VYNE Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92941V 308 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 92941V 308 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Soleus Capital Master Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ( b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 703,868 (1) 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 703 ,868 (1) 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 703,868 (1) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.0% (2) 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) FI FOOTNOTES (1) The shares of common stock reported in this row are held by Soleus Capital Master Fund, L.P. (“Master Fund”). Soleus Capital, LLC (“Soleus Capital”) is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC (“SCG”) is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or for any other purpose, except to the extent of their respective pecuniary interests therein. (2) This percentage is calculated based upon 13,957,324 shares of the common stock of the Issuer (“Common Stock”) outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the period ended September 30, 2023 filed with the Securities and Exchange Commission on November 13, 2023 (the “Form 10-Q”). 2 CUSIP No. 92941V 308 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Soleus Capital, LLC 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ( b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 703,868 (1) 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 703,868 (1) 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 703,868 (1) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.0% (2) 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO FOOTNOTES (1) The shares of common stock reported in this row are held by Master Fund. Soleus Capital is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. SCG is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein. (2) This percentage is calculated based upon 13,957,324 shares of Common Stock outstanding as of November 3, 2023, as reported in the Form 10-Q. 3 CUSIP No. 92941V 308 1 NAMES OF

View Full Filing

View this SC 13G/A filing on SEC EDGAR